NERV - Minerva Neurosciences, Inc.

7.94
-0.060   -0.756%

Share volume: 354,605
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$8.00
-0.06
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
32.11%
1 Month
25.43%
3 Months
94.61%
6 Months
272.77%
1 Year
412.26%
2 Year
182.56%
Key data
Stock price
$7.94
P/E Ratio 
0.00
DAY RANGE
$7.59 - $8.56
EPS 
-$1.85
52 WEEK RANGE
$1.15 - $12.46
52 WEEK CHANGE
$372.62
MARKET CAP 
14.721 M
YIELD 
N/A
SHARES OUTSTANDING 
6.993 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-30-2025
BETA 
-0.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$297,298
AVERAGE 30 VOLUME 
$178,507
Company detail
CEO: Rémy H. Luthringer
Region: US
Website: minervaneurosciences.com
Employees: 9
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.

Recent news